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Abstract
Low translational yield for stroke may reflect the focus of discovery science on rodents rather than humans. Just how little is
known about human neuronal ischaemic responses is confirmed by systematic review and meta-analysis revealing that data for
the most commonly used SH-SY5Y human cells comprises only 84 papers. Oxygen-glucose deprivation, H2O2, hypoxia,
glucose-deprivation and glutamate excitotoxicity yielded − 58, − 61, − 29, − 45 and − 49% injury, respectively, with a dose-
response relationship found only for H2O2 injury (R
2 = 29.29%, p < 0.002). Heterogeneity (I2 = 99.36%, df = 132, p < 0.0001)
was largely attributable to the methods used to detect injury (R2 = 44.77%, p < 0.000) with cell death assays detecting greater
injury than survival assays (− 71 vs − 47%, R2 = 28.64%, p < 0.000). Seventy-four percent of publications provided no descrip-
tion of differentiation status, but in the 26% that did, undifferentiated cells were susceptible to greater injury (R2 = 4.13%,
p < 0.047). One hundred and sixty-nine interventions improved average survival by 34.67% (p < 0.0001). Eighty-eight compar-
isons using oxygen-glucose deprivation found both benefit and harm, but studies using glutamate and H2O2 injury reported only
improvement. In studies using glucose deprivation, intervention generally worsened outcome. There was insufficient data to rank
individual interventions, but of the studies reporting greatest improvement (> 90% effect size), 7/13 were of herbal medicine
constituents (24.85% of the intervention dataset).We conclude that surprisingly little is known of the human neuronal response to
ischaemic injury, and that the large impact of methodology on outcome indicates that further model validation is required. Lack of
evidence for randomisation, blinding or power analysis suggests that the intervention data is at substantial risk of bias.
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Introduction
Translation in the field of stroke neuroprotection has proven to
be particularly challenging [1]. In part, this may be because
our understanding of human stroke pathophysiology is incom-
plete, and consequently, we may not have targeted the right
cells or the right molecular processes within these cells [2]. At
present, our understanding of the processes of the ischaemic
cascade comes mainly from experiments in rodent grey matter
[3] and remarkably little seems to be known of the human
neural ischaemic response.
To begin to systematise our knowledge of human neuron
ischaemic responses, we chose to identify the cell types stud-
ied within the human dataset because their names are unam-
biguous and then to select the most frequently used cell types
for systematic review and meta-analysis. We used the SWIFT-
Review software [4] developed by SCIOME to perform a
word frequency analysis to identify the cell types (with the
search term Bcells^) used within the titles and abstracts of the
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PubMed component of our initial search (at this time SWIFT
only worked directly with PubMed). This search revealed that
a much smaller number of papers explicitly identified the cell
type they used, and amongst these, human neuroblastoma-
derived SH-SY5Y cells are by far the most commonly used
human cell type (Table 1). Therefore, it was decided to con-
centrate on this cell type and to systematically search the lit-
erature for studies investigating ischaemia-related injuries in
SH-SY5Y cell culture.
The ischaemic cascade starts with blood flow and energy
supply reduction [5], which subsequently leads to
excitotoxicity, oxidative stress, and cell death [6, 7].
Ischaemic injury to cells in vitro is induced by hypoxia [8],
glucose deprivation [9] and the combination of oxygen and
glucose deprivation (OGD) [10] to model energy deprivation.
Application of glutamate/N-methyl-D-aspartate (NMDA) is
used to model excitotoxicity [11], and H2O2 [12] and sodium
nitroprusside (SNP) [13] are used to model oxidative stress.
Tumour necrosis factor-α (TNF-α) has been given to cause
nuclear factor-kappa (NF-κB)-mediated cell damage [14].
Using these injury models, the responses of SH-SY5Y cell
lines have been studied to elucidate the roles of small mole-
cules and pathways involving in the ischaemic cascade. These
models have also been used as an in vitro platform to test the
neuroprotective efficacy of several compounds [12, 15, 16].
Therefore, meta-analysis and meta-regression were conducted
to investigate the responses of SH-SY5Y cells to different
injury models and interventions.
Material and Methods
Identification of Relevant Studies
Searching
Three databases, Pubmed, Embase and Web of Science, were
searched for the terms BSHSY5Y OR SH-SY5Y OR SH-SY-
5Y OR SHSY-5Y OR SH-SY^ AND Bbrain ischemia OR
brain ischaemia OR brain ischemic OR brain infarctions OR
brain infarction OR cerebral infarction OR cerebral infarctions
OR stroke OR ischemic stroke^ on 3 January 2017 (the
detailed search strategy is reported in Appendix 2).
The citations retrieved were pooled in Endnote 7, and du-
plicates were identified and removed using the built-in dupli-
cate removal tool. Screening of the titles and abstracts was
then performed by two independent reviewers (E.E., T.W./
S.M.) who were familiar with preclinical stroke research and
able to apply the inclusion and exclusion criteria detailed be-
low. Disagreements were adjudicated by a third person (A.A.)
who also worked in the stroke research field. Full texts were
then assessed for their eligibility as described below before
data extraction and meta-analysis.
Definition
A Bpublication^ was defined as a discrete piece of work (ex-
cluding abstracts) containing data from one or more experi-
ments, each of which may describe outcomes using multiple
experimental readouts. An Bindividual comparison^ was de-
fined as the contrast between readouts in a single injury cohort
compared with that in an untreated cohort or a single interven-
tion cohort compared with an appropriate injured control
cohort.
For many studies, the sample size and the number of tech-
nical replicates were unclear. We believe that in most in-
stances, the authors intended the Bn^ specified to indicate the
number of times each experiment had been repeated indepen-
dently on different days or in different experimental runs.
Therefore, we took a pragmatic approach of using the origi-
nating authors’ Bn^ to be the sample size applied to each ex-
periment. Because this number was generally so low, we did
not adjust the numbers for weight and considered each to be
an independent study. This was not the usual approach found
in systematic review and meta-analysis, but we felt that we
had little choice but to adopt this approach. The percentage of
publications where the authors indicated a difference between
Table 1 Most frequently used human cell lines in aforementioned
PubMed search identified by SWIFT
Human brain cell types used Abbreviated
designators
Document
frequency
Human neuroblastoma SH-SY5Y 139
SK-N-SH 27
SK-N-MC
IMR-5 8
IMR-32
IMR-90
Human terato-carcinoma-derived
neuron-like cells (Ntera2/D1)
NT2-N 11
Human glioblastoma cells U87 5
T98G 2
Human astrocytoma CCF-STTG1 2
U373 MG 1
1321N1 1
Human cortical neurons HCN-1A 2
Non-brain human cell lines used
Human umbilical vein endothelial cells HUVEC 28
Human umbilical cord blood cells
derived-mesenchymal stem cells
HUCB-MSC 3
Foetal human neural stem and progenitor
cells
fNPCs 2
PubMed search performed in 12 August 2014; SWIFT search performed
in May 2016
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technical replicates and the number of such replicates were
given in the BResults^ section.
Also, for the purposes of this study, we have considered the
SH-SY5Y cell line to be a single biological entity. Bn^ is not
the same as the number of individuals recruited into a clinical
trial or the number of animals used in an in vivo experiment,
but the number of times a particular experimental contrast has
been assessed.
Inclusion and Exclusion Criteria
We included controlled studies that quantified cell death or
survival as an outcome in SH-SY5Y cells after ischaemia-
related injury. This was limited to models of glucose depriva-
tion, hypoxia or combined oxygen glucose deprivation
(OGD), oxidative stress imposed by the application of H2O2
or sodium nitroprusside (SNP), and injury caused by gluta-
mate and TNF-α. Genetically modified SH-SY5Y studies
were only included under the aforementioned injury models.
To be included, studies needed to report sample sizes, mean of
control and injury, standard deviation or standard error, injury
duration and interventions. Study authors were contacted via
e-mail if these data were absent in the full papers.
We excluded studies without control groups or not
reporting any form of cell death/survival readout. We exclud-
ed studies reporting non-ischaemic-related injury models such
as the Parkinson’s disease model created by the application of
MPP+ or 6-OHDA and the Alzheimer disease model created
by the application of A-β. Studies where relevance to ischae-
mic injury was unclear were also excluded from analysis but
recorded for future examination. Toxicants targeting the final
common pathway of cell death were excluded from analysis
but also recorded for future analysis (Staurosporine/STS,
Thapsigargin/TG or other cell death inducers). Conference
abstracts were excluded.
Data Extraction
Outcomes of injury magnitude compared to uninjured cohorts
and of interventions compared against injury controls were
extracted. Only the dose or time which achieved the best
outcome/greatest injury was extracted from dose- or time-
dependent curves to reflect the best outcome of one
intervention/greatest level of injury. When a publication re-
ported more than one type of cell death or survival readout
(such as reporting both MTT and LDH in one study), we
considered these to be independent experiments and extracted
data for each of these. Where different outcome units or mea-
suring methods were used for a single readout (such as
propidium iodide (PI) staining of individual cells counted un-
der the microscope plus staining of PI measured by fluores-
cence activated cell sorting), we nested them into one group,
and the normalized mean differences were calculated.
Analysis
For each comparison of injury versus untreated controls, we
determined the normalised mean difference by calculating the
percentage of damage in the injury group. For each compari-
son of an intervention against injured controls, we calculated a
normalised effect size (normalised mean difference) as the
percentage of improvement (B+^ sign) or worsening (B−^ sign)
of outcomes [17]. Standard error was calculated as previously
described [18].
DerSimonian and Laired random effects weighted mean
difference meta-analysis was then used to calculate a summa-
ry estimate of injury/improvement magnitude in each and all
injury models under various circumstances. Results were pre-
sented as the percentage injury against untreated and
improvement/worsening of outcome after interventions in in-
jured cohorts with the 95% confidence interval (CI). The var-
iability of the outcomes assessed is presented as the heteroge-
neity statistic (Q) with n − 1 degrees of freedom.
The effects of covariates explaining the heterogeneity be-
tween studies were assessed using univariate meta-regression
with themetareg function in STATA/SE10, with a significance
level set at p < 0.05.
Study Quality
There were very few study quality checklists designed for
in vitro studies. The CRIS Guidelines (Checklist for
Reporting In-vitro Studies) were a series of concept notes
adapted from the CONSORT guidelines to improve study
quality in the dental research [19]. However, these were not
sufficient for our purpose. Therefore, we adapted the
reviewing criteria designed for the Nature Publication
Quality Improvement Project (NPQIP) study [20].
Eight categories were recorded: exclusion, randomisation,
blinding, sample size, figures and statistical representation of
data, definitions of statistical methods, implementation of sta-
tistical methods and measures, as well as reagents and cell
preparations. Each category included one or more specific
criteria (Supplementary Table 1), and if the publication met
the criteria, then 1 point was scored for each item, with a total
possible score of 20.
Results
Characteristics of Included Studies
Electronic searching identified 759 full publications with 429
potentially relevant articles screened for inclusion after re-
moval of duplicates. After screening, 150 met our prespecified
criteria, and 88 were eligible to be included in the analysis.
Seven ischaemia-related injury models were described in the
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included studies. Of these, five models (OGD, H2O2, hypoxia
alone, glucose deprivation alone, glutamate) from 84 publica-
tions were included in the meta-analysis (Fig. 1).
OGD was the most commonly used injury model (48 pub-
lications, 57.14%), followed by H2O2 (18 publications,
21.43%), while the other three models made up the remaining
21.43% of the publications (hypoxia only, 7 publications; glu-
cose deprivation only, 6 publications; and glutamate
excitotoxicity, 5 publications). One publication reported uti-
lizing both H2O2 and glutamate-induced injury [21]. Six ad-
ditional publications were included in a qualitative analysis.
Four of these publications used SNP to create oxidative injury
and another two used TNF-α in combination with hypoxic
injury in the same paper [22, 23]. In the publications providing
data for more than one injury model, the publication was
counted once and assigned to the injury model group which
supplied the most data. However, the individual comparisons
were extracted and analysed independently.
Meta-Analysis of the Effects of Ischaemic Injury
Induction Compared with Uninjured Controls
84 publications exploring five ischaemia-related injuries re-
ported cell damage/survival compared with that in uninjured
controls in 133 individual comparisons. Injury magnitude was
grouped according to the models the authors reported and
ranked according to their effect size.
There was significant between-study heterogeneity (I2 =
99.36%, degrees of freedom (df) = 132, p < 0.0001). The over-
all injury caused by the different ischaemic-related models
was very similar, with an average injury of − 55.04% (95%
CI − 59.96, − 50.12) (Fig. 2).
OGD models contributed to the largest number of studies
to the dataset (48 publications, 70 comparisons) and exhibited
a full-range injury exploration from almost 0 to 100% injury
with a mean injury of − 58.51% (95% CI − 63.42, − 53.6).
H2O2 injury (18 publications, 32 comparisons) was used over
a narrower injury range with an apparent plateau at − 90%
(three comparisons coming from one study) and a mean of
− 60.77% (95% CI − 68.29, − 53.25).
Much less data was available for glucose deprivation
alone (6 publications, 11 comparisons, − 45.2%, 95% CI
− 64.16, − 26.27), glutamate excitotoxicity (5 publica-
tions, 10 comparisons, − 49.43%, 95% CI − 61.4, −
37.45) and hypoxia (7 publications, 10 comparisons, −
28.98%, 95% CI − 71.04, 13.09). The glucose depriva-
tion data showed an unusual clustering, suggesting au-
thors to chose low, medium or high level of glucose
deprivation for their experiments. While all the afore-
mentioned models reported only damaging effects, the
hypoxia data was unusual in having three experimental
comparisons (from one paper [24]) which suggested the
presence of a hypoxia preconditioning effect. These
three models reported less injury than seen after OGD
and H2O2.
Fig. 1 Flow diagram of publication selection. N number of publications
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Study Characteristics Accounting
for the Heterogeneity of Injury Magnitude
To investigate the factors that influenced injury efficacy, we
used meta-regression to identify facets of the experimental
design that contributed to outcome heterogeneity. The three
outliers from the hypoxia model data suggested a precondi-
tioning effect were excluded from this meta-regression. Three
study characteristics accounted for a significant proportion of
the between-study heterogeneity in reporting cell damage.
The damage detection methodology accounted for most of
the observed heterogeneity (R2 = 44.77%, p < 0.000). Nine
methods were used to detect cellular injury in the 130 com-
parisons. The MTT assay was the most frequently used meth-
od (52 comparisons, 40% of the data) and detected an average
injury of − 50.42% (95% CI − 55.16, − 45.68). By contrast,
the second most commonly used method, the LDH assay (41
comparisons, 31.54% of the data), reported − 67.19% injury
(95% CI − 74.62, − 59.76). The MTT and LDH assay alone
accounted for 71.54% (93 comparisons) of the assessment
methods. Overall, methodologies depending on cell counting
tend to report more damage (PI − 80.68%, 95% CI − 91.24, −
30.72; DAPI − 76.39%, 95% CI − 98.37, − 54.41). The only
exception was the trypan blue exclusion assay (7 compari-
sons), which appeared to underestimate the injury (−
23.11%, 95% CI − 36.63, − 9.59). Of the other methods, the
TUNEL assay reported the highest injury detection (3 com-
parisons, − 73.52%, 95% CI − 96.63, − 49.94) while the MTS
assay (3 comparisons, − 48.75%, 95% CI − 70.75, − 26.74),
the CCK8 assay (5 comparisons, − 41.52%, 95% CI − 57.21,
− 25.84) and the WST-1 assay (2 comparisons, − 30.02%,
95% CI − 53.66, − 6.38) all reported smaller levels of injury
on average (Fig. 3).
Each of the nine detection methods could be classified as
either measures of cell death (60 comparisons, 46.15% of the
data: LDH, DAPI counting, PI (counting and FACS) and
TUNEL assay) or survival (70 comparisons, 53.85% of the
data: MTT, CCK8, MTS, WST-1 and PI+FDA). Methods be-
longing to the cell death category tended to report greater
injury (− 70.57%, 95% CI − 75.8, − 65.33) than cell survival
Fig. 2 Summary of data included
in the meta-analysis with
individual comparisons grouped
by five in vitro ischaemic models.
Data are ranked according to their
injury magnitude against
untreated controls. The shaded
grey bar represents the 95% CI of
the individual injuries. The
horizontal error bars represent the
95% CI for the individual
estimates
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methods (− 47.14%, 95% CI − 54.07, − 40.2) (R2 = 28.64%,
p < 0.000) (Fig. 4a). Of comparisons, 41.67% used multiple
detection methods; however, no significant difference in out-
come was detected compared to those only assessed by a
single method.
The third parameter contributing significantly to the hetero-
geneity was whether the cells were manipulated prior to ex-
perimentation. Such manipulation was common where exper-
iments tried to modify the phenotype of the cells, for example,
see Boltze and colleagues [25]. Most publications (96 publi-
cations, 73.85%) provided no description of the cell differen-
tiation status. Thirty-four publications (26.15%) reported spe-
cifically whether the SH-SY5Y cells were differentiated (19
comparisons), undifferentiated (8 comparisons) or transfected
(19 comparisons) (R2 = 4.13%, p < 0.047). Undifferentiated
cells were susceptible to the greatest injury (− 77.42%, 95%
CI − 93.64, − 61.2) followed by transfected cells (− 64.08%,
95% CI − 80.88, − 47.29). Differentiated cells were less sen-
sitive to injury (− 57.47%, 95% CI − 68.81, − 46.13). Studies
where the differentiation status was unspecified showed sim-
ilar levels of injury to this latter group (− 55.07%, 95% CI −
59.6, − 50.53) (Fig. 4b).
There was no detectable effect of injury duration, reperfu-
sion duration, time of assessment, seeding density, O2
concentration used during the injury model or of culture me-
dium used.
Analysis of OGD and H2O2 Data Subsets
A large proportion of the data were obtained from just the
OGD (48 publications, 70 comparisons) and H2O2 datasets
(18 publications, 32 comparisons). Subgroup analysis re-
vealed that overall heterogeneity (Q) fell in these data subsets
(total: Q = 28,006.95; OGD: Q = 5138.64; H2O2: Q =
3086.25).
For the OGD dataset, the damage detection method used
accounted for a large part of this heterogeneity (R2 = 49.87%,
p = 0.0000). This was consistent with a similar observation
from the total dataset. In the H2O2 data, the type of cell ma-
nipulation contributed significantly more to the observed het-
erogeneity (R2 = 18.53%, p < 0.032, vs total dataset: R2 =
4.13, p < 0.047).
For H2O2-mediated injury, a dose-response relationship
contributed significantly to the observed heterogeneity (R2 =
29.29%, p < 0.002). The majority of experiments chose H2O2
concentrations of less than 200 μM (13 comparisons) and
produced a milder injury (− 52.98%, 95% CI − 63.98, −
41.98) than those using concentrations of between 200 and
Fig. 3 Influence of outcome
detection methods on the degree
of cellular injury reported in the
control cohorts. The shaded grey
bar represents the 95%
confidence limits of the global
estimate. The vertical error bars
represent the 95% confidence
intervals for the individual
estimates. The width of each
column represents the volume of
available data
Fig. 4 Influence of a damage detection methods and b prior cell
manipulation, on cellular injury detected in untreated control cells. The
shaded grey bar represents the 95% confidence limits of the global
estimate. The vertical error bars represent the 95% confidence intervals
for the individual estimates. The width of each column represents to
volume of available data
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400 μM (7 comparisons, − 55.07%, 95% CI − 73.57, − 36.58)
or 600–800 μM (2 comparisons, − 75.33%, 95% CI − 104.65,
− 46.01) and 800–1000 μM (8 comparisons, − 81.18%, 95%
CI − 100.69, − 61.66) (Fig. 5). No dose response could be
detected for the other injury models.
Other experimental variables (OGD: cell manipulation, gas
composition, medium ingredients, injury duration or reperfu-
sion status; H2O2: damage detection method, injury time or
seeding density) did not account for significant proportions of
the observed heterogeneity.
Meta-Analysis of Intervention After In Vitro Ischaemic
Injury
In addition to the analysis of experimental variables on the
impact on outcomes in untreated controls, we also sought to
investigate the effects of the intervention arms of the included
studies on outcome.
Eighty publications examined 169 intervention compari-
sons from the top five in vitro ischaemia models. Four publi-
cations (one using glucose deprivation [26], one using hypox-
ia [25], and two using OGD [27, 28]) were excluded because
no intervention was reported or it was reported in non-
ischaemic models. The OGD model was used to study the
largest number of interventions (88 comparisons), followed
by H2O2 (33 comparisons), hypoxia (15 comparisons), gluta-
mate excitotoxicity (10 comparisons) and glucose deprivation
alone (7 comparisons). Multiple interventions were frequently
reported in one publication, and they were treated as individ-
ual comparisons for the purposes of this analysis
(Supplementary Table 6).
Heterogeneity was greater overall where an intervention
was applied (Q = 42,108, 169 comparisons) than for the data
for injury alone in untreated cohorts (Q = 28,006 over 133
comparisons). Overall, the interventions improved cell
survival by 34.67% (95% CI 27.7, 41.62, I2 = 99.48%,
p < 0.0001) across the five models. Interestingly, glutamate
and H2O2 injury were the only two models where only im-
proved outcomes were reported with 64% (95% CI 46.2,
81.81) and 47.12% (95% CI 37.35, 56.88) improvement, re-
spectively. In contrast, negative outcomes were common in
the models of OGD and its subcomponent models (hypoxia
and glucose deprivation only), and thus led to smaller effect
sizes (OGD 35.84%, 95% CI 26.94, 44.73; hypoxia 6.8%,
95% CI − 23.38, 36.98). Glucose deprivation was the only
model to give rise an overall worsening of outcome after the
interventions (− 20.8%, 95% CI − 54.32, 12.72) (Fig. 6).
Overall, we found that 21/169 comparisons reported nega-
tive outcomes of which 10 involved genome manipulations.
These studies appeared to be consistent with the authors who
intent to study mechanisms.
Of all intervention comparisons, 24.85% utilized herbal or
traditional medicines or their derivates which improved out-
come by 65.12% on average. Of the studies reporting the
greatest improvement (> 90% effect size), more than half
(7/13 comparisons) were studies of the bioactive constituents
of herbal medicines (Supplementary Table 2).
Mechanism of Action of Interventions Studied
The most commonly studied molecules were only represented
in two or three independent studies. Therefore, there was in-
sufficient data for meta-analytical exploration of their compar-
ative effects.
When we grouped intervention targets into single or mixed
ischaemia-related mechanisms according to the author’s orig-
inal statements, we found that 91/169 (53.85%) experiments
studied interventions targeting a single mechanism, of which
half (46/91 comparisons, 50.55%) targeted apoptosis. This
was followed by antioxidant-related mechanisms (32/91 com-
parisons, 35.16%), which was also the only targeting mecha-
nism studied in all the aforementioned models. The remainder
(14%) studied excitotoxicity: 3 comparisons, mitochondrial
protection; 3 comparisons, growth factor secretion; 4 compar-
isons; and axonal growth, 3 comparisons (Supplementary
Table 3).
Interventions targeting multiple mechanisms were investi-
gated in 78 comparisons. Seventy-six comparisons of these
studied two mechanisms in 11 different combinations. One
study referred to three potential mechanisms for their interven-
tional drugs but no experiments to identify the mechanism
were performed [9]. Drugs modifying apoptosis and oxidative
biology were the most commonly studied pairs (32/76 com-
parisons, 42.11%). This was particularly true for the H2O2
injury studies where 17/17 studies all used such a combination
(Supplementary Table 4).
Researchers using the OGD injury model studied the
greatest range of intervention mechanisms in combination
Fig. 5 Influence of H2O2 concentration on injury magnitude in untreated
control cohorts. Circle diameter is proportional to study size
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(9/11 mechanisms). Apoptosis was the most commonly stud-
ied mechanism both singly (40/52 comparisons, 77%) or in
combination with antioxidant interventions (both have 13
comparisons, 32.5%). This pattern was reversed for H2O2 in-
jury (14/22 comparisons, 63.64%, studied antioxidant mech-
anisms singly or 17/17 comparisons, 100%, studied antioxi-
dant and anti-apoptotic mechanisms).
Study Quality
In systematic review and meta-analysis, which is most often
used to determine a therapeutic effect in clinical studies, a key
determinant of the value of the analysis is the quality of the
included studies. This is most often ascertained by formal risk
of bias analysis [29] or by application of a simple checklist in
pre-clinical studies, where understanding of the need to report
such issues lags behind the clinical field. However, in in vitro
research, these issues have not gained widespread recognition
as potential sources of experimental error. Therefore, in our
study, we had only a limited ability to assess study quality.
We reported and scored the items using our modified study
quality checklist for each included publication from the five
most commonly used ischaemia- re la ted models
(Supplementary Table 5). Study design features which help
reduce bias, such as randomisation, blinding, sample size cal-
culation and description of inclusion and exclusion criteria,
were extremely poorly reported. Only one publication in
H2O2 injury and one publication on OGD injury out of a total
of 84 publications reported their exclusion criteria (2.38%),
and the same study was also the only study to report a sample
size calculation (1.19%). None of the publications reported
either randomisation or blinding in their full text. While BN^
was reported in more than 95% of the publications, there was
generally a poor description of what BN^ stood for (wells/
plates/microscope fields). Only 19/84 publications (22.62%)
gave a clear statement of whether the samples represented
technical or biologically relevant replicates, and 29/84
(34.52%) described how many times the experiment was rep-
licated. Cell preparation was also poorly reported, with only
half of the publications (54.76%) describing the sources of
Fig. 6 Summary of interventional
data included in the meta-analysis
from five in vitro ischaemic
models. Data are ranked
according to their effect on
change after cell damage from
each injury. The shaded grey bar
represents the 95% CI of the
individual injuries. The vertical
error bars represent the 95% CI
for the individual estimates
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their cell lines. Mycoplasma contamination testing and cell
line authentication were not reported in any of the included
publications.
Using the modified NPQIP score sheet (maximum score
20) [20], the mean quality score for each of the models did not
differ significantly, with glucose deprivation achieving the
highest score of 8.67 followed by three similar models:
H2O2, 7.56; OGD, 7.33; and glutamate, 7.4. The hypoxia
model gave rise the lowest score, at only 6.86.
In the future, in vitro researchers need to determine whether
such issues impact the validity of their results.
Discussion
Initial scoping of the citation databases indicated that our de-
sire to use systematic review and meta-analysis to explore and
ultimately understand the in vitro data available on the human
ischaemic cascade was likely to prove intractable because of
the number and heterogeneity of the available publications.
Therefore, we used a word frequency analysis of the titles
and abstracts of these published data to refine our question.
This analysis revealed that the SH-SY5Y cell line was the
most commonly used tool in human in vitro ischaemic
research.
Systematic review and meta-analysis of the studies using
this cell line indicated that the use of fivemodels of ischaemia-
related injury dominated this literature: oxygen and glucose
deprivation, H2O2-induced oxidative stress, oxygen depriva-
tion, glucose deprivation and glutamate excitotoxicity.
The pattern of outcomes revealed important information
about both researchers’ experimental choices and the biology
of the systems. In the control arms of the publications, there
was substantial heterogeneity. Nearly half of this could be
explained by the methods used to determine cell fate with
methods detecting cell death producing greater estimates of
damage than methods detecting the proportion of survival
cells. We also found that damage detection methods utilizing
microscopic subfield analysis tended to detect more injury
compared with Bwhole-well^-based analysis with the excep-
tion of the trypan blue method.
Whether the cells had been manipulated prior to the injury
also accounted for a significant proportion of heterogeneity
with undifferentiated cells appearing to be more susceptible
to injury than differentiated neurons. For H2O2-injured cells,
the type of cell manipulation accounted for nearly 20% of the
observed heterogeneity. For the majority of publications, there
was no clear description of the differentiation status of the
cells used and hence, we classified this as Bunspecified^. In
the overall analysis, this large group behaved very differently
from the cells specified as undifferentiated. However, of the
eight studies using undifferentiated cells, the worst outcomes
were seen in those without the equivalent of a reperfusion
period; this suggests the possibility that oxygenation status
might offer an explanation. However, further work is required
to clarify this issue. Certainly, we would not expect normal
human neural progenitors to be more sensitive to injury than
their highly arborised and electrically active mature deriva-
tives as observation found that differentiated cells require
more oxygen and are therefore more susceptible to injury [30].
For H2O2-injured cells, a clear dose-response relationship
was detectable. Such a response was not evident for the other
injuries and nor was there a clear influence of injury duration.
For OGD and the related hypoxia and glucose deprivation
models, this might be interpreted as the result of the use of a
highly optimized set of uniform experimental conditions.
However, the broad range of levels of damage detected in
these control circumstances (from nearly 0 to 100% injury)
does not support this interpretation. Indeed, for hypoxia alone,
the data suggested that under some circumstances, a protective
effect is possible. The highly clustered range of outcomes for
just glucose deprivation also suggests some unidentified sys-
tematic effect.
Interestingly, for both H2O2- and glutamate-induced injury,
there appeared to be a ceiling effect, suggesting that a propor-
tion of the cultured cells were resistant to these injuries.
SH-SY5Y is a highly proliferate cell line, and others have
previously reported that seeding density influences outcomes
[31]. However, we found no relationship between starting
seeding density (53.6% of studies reported this data) and the
outcomes.
Analysis of the intervention arms of the included publica-
tions proved more difficult than expected because of the
breadth of interventions studied (Supplementary Table 6).
No single Bdrug^ was represented sufficiently in the dataset
to estimate the effect size for comparison purposes. Grouping
interventions by the broad mechanistic classes indicated in the
originating authors’ text did however provide useful data.
There was an overwhelming focus on apoptotic and oxidative
biology mechanisms. Given the range of mechanisms targeted
in preclinical animal studies [1] and in clinical trials [32] for
ischaemic stroke, this was surprising. Also surprising was the
high proportion of studies on herbal or traditional medicines
and their high ranking in terms of protective effect. Overall,
the lack of specificity by authors on whether their study was to
explore a molecule therapeutic potential or whether the exper-
imental purpose was to explore mechanisms of injury made
in-depth analysis of this impractical.
In clinical and preclinical animal systematic review and
meta-analysis, assessment of the risk of bias within a publica-
tion or cohort of publications provides important data
allowing readers to judge whether the work is worthy of fur-
ther investigation (follow-up experiments, progress to clinical
trials). In this cohort of publications, reporting of these issues
(randomisation, blinding, inclusion and exclusion criteria, a
priori power calculations) is so poor that we have to conclude
572 Transl. Stroke Res. (2018) 9:564–574
that the risk of bias is very high. A recent systematic review of
the use of SH-SY5Y to model Parkinson’s disease did not
perform meta-analysis and made no comments of the likely
quality of the studies included in the review [33].
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